Axon Enterprise, Inc. (NASDAQ:AXON) Director Sells $960,492.00 in Stock

Axon Enterprise, Inc. (NASDAQ:AXON) Director Caitlin Elizabeth Kalinowski sold 1,300 shares of the company’s stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $738.84, for a total transaction of $960,492.00. Following the sale, the director now owns 4,829 shares in the company, valued at $3,567,858.36. The trade was a 21.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Axon Enterprise Trading Up 0.1%

Shares of Axon Enterprise stock traded up $0.43 on Tuesday, hitting $742.75. The stock had a trading volume of 383,468 shares, compared to its average volume of 751,632. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. Axon Enterprise, Inc. has a one year low of $273.52 and a one year high of $744.51. The stock’s 50-day simple moving average is $588.30 and its two-hundred day simple moving average is $597.92. The stock has a market cap of $57.82 billion, a price-to-earnings ratio of 191.93, a PEG ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.07. The business had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The company’s revenue was up 31.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.15 EPS. As a group, sell-side analysts predict that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on AXON shares. Needham & Company LLC raised their target price on Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. Northcoast Research lowered shares of Axon Enterprise from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 19th. Barclays upped their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an “overweight” rating in a report on Friday, May 9th. JMP Securities reiterated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. Finally, The Goldman Sachs Group boosted their target price on Axon Enterprise from $730.00 to $830.00 and gave the stock a “buy” rating in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and a consensus price target of $652.73.

Hedge Funds Weigh In On Axon Enterprise

Institutional investors have recently added to or reduced their stakes in the company. TCTC Holdings LLC boosted its holdings in Axon Enterprise by 75.0% in the first quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 24 shares in the last quarter. Fourth Dimension Wealth LLC purchased a new stake in Axon Enterprise during the 4th quarter valued at about $30,000. Bartlett & CO. Wealth Management LLC increased its stake in Axon Enterprise by 132.0% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 33 shares in the last quarter. Banque Transatlantique SA purchased a new position in Axon Enterprise in the first quarter worth about $31,000. Finally, Catalyst Capital Advisors LLC bought a new position in shares of Axon Enterprise in the first quarter worth approximately $32,000. Institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.